Editor’s note: This is a developing news story. Please check back soon for updates.
Two investigational agents from Kodiak Sciences helped improve vision in patients with wet age-related macular degeneration, according to a press release.
In the phase 3 DAYBREAK study, researchers assessed Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) vs. Eylea (aflibercept, Regeneron) in patients wet AMD. Zenkuda is an anti-VEGF that uses Kodiak’s antibody biopolymer conjugate (ABC) platform and is designed to maintain more durable drug levels. KSI-501 is an anti-IL-6, VEGF-trap